TLSA | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 20%

Performance

5 Days

-11.75%

1 Month

-41.92%

3 Months

22.31%

6 Months

-4.23%

1 Year

111.31%

2 Year

-10.87%

Key data

Stock price

$0.90

P/E Ratio

0.00

DAY RANGE

$0.83 - $0.95

EPS

N/A

52 WEEK RANGE

$0.41 - $1.91

52 WEEK CHANGE

$101.48

MARKET CAP

103.088 M

YIELD

N/A

SHARES OUTSTANDING

103.088 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

-1.22

PUBLIC FLOAT

AVERAGE 10 VOLUME

$300,132

AVERAGE 30 VOLUME

$527,563

Company detail

CEO: Gabriele Marco Antonio Cerrone
Region: US
Website: tizianalifesciences.com
Employees: 8
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Tiziana Life Sciences plc focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

TLSA - Tiziana Life Sciences Ltd